In 2005, Albany Molecular Research Inc. (AMRI) announced a licensing agreement with Bristol-Myers Squibb involving AMRI’s broad program of compounds encompassing biogenic amine reuptake inhibitors. Under the terms of the agreement, Bristol-Myers Squibb received an exclusive license to develop and commercialize these inhibitors, which would ultimately be used for the improved treatment of depression and other central nervous system disorders.
In June 2008, Bristol-Myers Squibb submitted a Clinical Trial Application (CTA), which enabled initiation of Phase I studies on a biogenic amine reuptake inhibitor. The inhibitor acts at multiple targets and may represent a new class of therapeutic agents that could lead to improved treatment for depression or other CNS disease indications. In May 2011 AMRI announced the progression of this compound into Phase II clinical studies. In September 2008, BMS selected a second compound from the collaboration to enter preclinical development. In May 2009, a CTA was filed in Sweden to progress this compound into Phase I studies.